You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
A Transparent Surgical Mask to Improve Patient/Caregiver Communication, Minimize Errors and Increase Patient SatisfactionSBC: FaceView Mask, LLC Topic: NINR
PROJECT SUMMARY Approximately 4% of people in the US are either deaf or hard of hearing, equating to more than 13 million people. Of these, approximately 12 million people over the age of 5 years have difficulty hearing normal conversation even when using a hearing aid. Hearing difficulties affect all age groups and present significant challenges in daily life. These challenges are particularly ac ...STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
Personalized anesthetic brain monitoring:Developing novel systems, sensors, and algorithms for aging, dementia, and Alzheimers disease patientsSBC: PASCALL Systems, Incorporated Topic: R
PROJECT SUMMARY In the United States, nearly 100,000 patients receive general anesthesia and sedation daily to safely undergo surgical and non-surgical procedures. A high proportion of these patients are older than 65 years of age. These older patients are at higher risk of post-operative delirium and cognitive dysfunction. Many of these older patients have dementia, including mild cognitive impai ...STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: General Biophysics LLC Topic: NIA
Administrative Supplement Application PA-20-272 Xenon gas treatment to modulate microglia in neurodegenerative diseases (R41AG073059) ABSTRACT ABSTRACT FROM ORIGINAL APPLICATION Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder. Emerging evidence shows that homeostatic dysregulation of the brain immune system, especially that orchestrated by microglia, plays a significant ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: 1910 GENETICS INC. Topic: 105
PROJECT SUMMARY Never in the history of the United States has the unmet medical need to develop novel, non-opioid therapeutics for chronic pain been more urgent than it is today. More than 65 million US adults suffer from chronic pain, resulting in almost $635 billion in annual healthcare costs. Despite their limited efficacy, and potential for addiction, tolerance, and impaired motor performance, ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: Vesicle Therapeutics Inc. Topic: NHLBI
Project Summary Vesicle Therapeutics Inc aims to develop and commercialize a new therapy for homozygous familial hypercholesterolemia (hoFH). A majority of hoFH is caused by mutations in both alleles of the gene encoding the LDL receptor (LDLR). Since the efficacy of both statins and PCSK9 antibody therapies largely depends on functional LDL receptors, patients with hoFH show limited responses to ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
Empowering providers to improve care for disadvantaged patients: design and prototype testing of novel user interface for electronic health recordsSBC: ASP.MD Topic: 102
PROJECT SUMMARY There is an emerging digital divide in healthcare between those who care for disadvantaged patients and those who care for less vulnerable populations. In the past decade, electronic health record (EHR) adoption and use has increased but unequally. Providers caring for disadvantaged populations are less likely to have and use advanced EHRs with sophisticated clinical decision suppo ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: MYCOBACTERIA THERAPEUTICS CORPORATION Topic: NCCIH
Project Summary Immunoregulation, i.e., balanced expression of regulatory and effector T cells, is thought to be compromised in modern high-income settings due in part to reduced contact with commensal and environmentally derived bacteria, also known as “old friends”. Failed immunoregulation is thought to be one factor contributing to recent increases in stress-related and chronic inflammatory ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: Cohere-Med, Inc. Topic: 300
Abstract This fast-track STTR application proposes to enhance, validate, and scale Sepsis Watch, a deep learning sepsis detection and management system built using data from the Emergency Department (ED) Duke University Hospital (DUH). The proposal will extend and enhance Sepsis Watch to EDs, general inpatient wards, and intensive care unit (ICU) settings across multiple health systems in the Unit ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
Assessment of mobile application-delivered lighting interventions for reducing circadian disruption in shift workersSBC: ARCASCOPE INC. Topic: NHLBI
PROJECT SUMMARY Shift workers experience profound circadian disruption, which can have deleterious long term effects on their health and quality of life. Mood, fatigue, and performance can be improved in shift workers by moving the timing of their peak circadian drive to sleep outside the hours they are expected to work. This can be achieved with a targeted lighting intervention, as light is the p ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
A multitargeted nanocarrier inhibitor of undruggable transcription factors for treating castration resistant prostate cancerSBC: PARABON NANOLABS, INC. Topic: 102
Project Summary This project addresses the critical need for treatments of castration resistant prostate cancer (CRPC) by proposing to engineer and develop a novel, nanostructured pharmaceutical (P-TRIS5) which will target tumor cells and deliver two potent, synergistic therapeutics (an siRNA and a small molecule) to inhibit the androgen receptor and RUNX, two commonly implicated transcription fac ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health